

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM620566

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as Collateral Agent		01/13/2021	Bank: SWITZERLAND

## RECEIVING PARTY DATA

<b>Name:</b>	JAGUAR HOLDING COMPANY I
<b>Street Address:</b>	929 North Front Street
<b>City:</b>	Wilmington
<b>State/Country:</b>	DELAWARE
<b>Postal Code:</b>	28401
<b>Entity Type:</b>	Corporation: DELAWARE
<b>Name:</b>	Jaguar Holding Company II
<b>Street Address:</b>	929 North Front Street
<b>City:</b>	Wilmington
<b>State/Country:</b>	DELAWARE
<b>Postal Code:</b>	28401
<b>Entity Type:</b>	Corporation: DELAWARE
<b>Name:</b>	Pharmaceutical Product Development, LLC
<b>Street Address:</b>	929 North Front Street
<b>City:</b>	Wilmington
<b>State/Country:</b>	DELAWARE
<b>Postal Code:</b>	28401
<b>Entity Type:</b>	Limited Liability Company: DELAWARE

## PROPERTY NUMBERS Total: 11

Property Type	Number	Word Mark
<b>Registration Number:</b>	4959657	E-RS
<b>Registration Number:</b>	4555020	EVIDERA
<b>Registration Number:</b>	4555019	EVIDERA
<b>Registration Number:</b>	4728703	EXACT-PRO INITIATIVE
<b>Registration Number:</b>	5055755	EVALYTICA
<b>Registration Number:</b>	4396586	MODEL-IT

TRADEMARK

Property Type	Number	Word Mark
Registration Number:	5042519	EVALYTICA
Serial Number:	86743720	EVALUATING RESPIRATORY SYMPTOMS
Serial Number:	87094505	EVIDICE
Serial Number:	87096316	IVALUE SUITE
Serial Number:	87094588	RX EVIDICE

**CORRESPONDENCE DATA**

**Fax Number:**

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 800-494-5225

**Email:** ipteam@cogencyglobal.com

**Correspondent Name:** Stewart Walsh

**Address Line 1:** 1025 Vermont Ave NW, Suite 1130

**Address Line 2:** COGENCY GLOBAL Inc.

**Address Line 4:** Washington, D.C. 20005

<b>ATTORNEY DOCKET NUMBER:</b>	1315278Â TM B
<b>NAME OF SUBMITTER:</b>	Hannah Adkins
<b>SIGNATURE:</b>	/Hannah Adkins/
<b>DATE SIGNED:</b>	01/15/2021

**Total Attachments: 4**

- source=B PPD - Trademark Release RF 5926.0044 (Executed)#page2.tif
- source=B PPD - Trademark Release RF 5926.0044 (Executed)#page3.tif
- source=B PPD - Trademark Release RF 5926.0044 (Executed)#page4.tif
- source=B PPD - Trademark Release RF 5926.0044 (Executed)#page5.tif

RELEASE OF TRADEMARK SECURITY INTERESTS dated as of January 13, 2021 (this “Release”), by CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as collateral agent (the “Collateral Agent”) for the Secured Parties, in favor of the Grantors (defined below). Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Credit Agreement, the Security Agreement or the IP Security Agreement, as applicable, referred to below.

A. Reference is made to (i) the Credit Agreement dated as of August 18, 2015 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), among Jaguar Holding Company I, a Delaware corporation (“Holdings”), Jaguar Holding Company II, a Delaware corporation (the “Parent Borrower”), Pharmaceutical Product Development, LLC, a Delaware limited liability company (the “Subsidiary Borrower”), the Lenders, the L/C Issuers and the Collateral Agent, (ii) the Security Agreement dated as of August 18, 2015 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”), among the Grantors from time to time party thereto and the Collateral Agent and (iii) the Intellectual Property Security Agreement dated as of November 10, 2016, among the Grantors listed therein and the Collateral Agent (as amended, amended and restated, supplemented or otherwise modified from time to time, the “IP Security Agreement”) (such documents set forth in clauses (i) through (iii), the “Security Documents”).

B. Pursuant to the Security Documents, the Persons listed on Schedule I hereto (the “Grantors”) collaterally assigned, pledged and granted to the Collateral Agent, for the benefit of the Secured Parties, a security interest in, among other property, the Trademark Collateral (as hereinafter defined), which security interest was recorded with the United States Patent & Trademark Office on November 18, 2016 at Reel/Frame 5926/0044.

C. Pursuant to the Payoff Letter dated as of January 12, 2021, among Holdings, the Parent Borrower, the Subsidiary Borrower and the Collateral Agent, the Collateral Agent agreed to release any and all security interests it may have in the Trademark Collateral pursuant to the Security Documents.

Accordingly, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent does hereby release, relinquish and discharge its security interest it has in and to all of the following in each case to the extent created, granted or otherwise established under any Security Document (the “Trademark Collateral”):

With respect to each Grantor, all of such Grantor’s right title and interest in and to the following:

(i) the trademarks and service marks owned by such Grantor, including those of such Grantor set forth on Schedule I hereto, together with the goodwill symbolized thereby;

(ii) all reissues, divisionals, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the foregoing, all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of such Grantor accruing thereunder or pertaining thereto;

(iii) any and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and

(iv) any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the Trademark Collateral of or arising from any of the foregoing.

The Collateral Agent hereby re-assigns to each Grantor any right, title or interest it may have in the Trademark Collateral of such Grantor, without representation or warranty of any kind. The Collateral Agent authorizes each Grantor (or their designee, or any person or entity hereafter having any right title or interest in the Trademark Collateral of such Grantor) to make filings with the United States Patent and Trademark Office and other necessary filings, in each case at the expense of such Grantor, to evidence the release and termination of the Collateral Agent's security interests in the Trademark Collateral of such Grantor.

Sections 4 and 6 of the IP Security Agreement are incorporated herein by reference, *mutatis mutandis*.

[The remainder of this page intentionally left blank]

IN WITNESS WHEREOF, the Collateral Agent has caused this Release to be duly executed as of the day and year first above written.

CREDIT SUISSE AG, CAYMAN ISLANDS  
BRANCH, as Collateral Agent,

By 

Name: Whitney Gaston

Title: Authorized Signatory

By 

Name: Komal Shah

Title: Authorized Signatory

[Signature Page to Trademark Release]

**TRADEMARK**  
**REEL: 007163 FRAME: 0111**

Schedule I

**Trademarks**

**Registered Trademarks**

<b>Owner</b>	<b>Mark</b>	<b>Registration Number</b>	<b>Expiration Date</b>
Evidera, Inc.	E-RS	4,959,657	May 17, 2026
Evidera, Inc.	EVIDERA	4,555,020	June 24, 2024
Evidera, Inc.	EVIDERA	4,555,019	June 24, 2024
Evidera, Inc.	Exact-Pro Initiative (and Design)	4,728,703	April 28, 2025
Evalytica, Inc.	EVALYTICA (mark only)	5055755	October 4, 2026
Evidera, Inc.	Model-IT	4,396,586	September 3, 2023
Evalytica, Inc.	EVALYTICA (mark and design)	5,042,519	September 13, 2026

**Trademark Applications**

<b>Owner</b>	<b>Mark</b>	<b>Application Number</b>	<b>Expiration Date</b>
Evidera, Inc.	EVALUATING RESPIRATORY SYMPTOMS	86/743,720	N/A
Evidera, Inc.	EviDICE (Text and Logo)	87/094,505	N/A
Evidera, Inc.	IValue Suite	87/096,316	N/A
Evidera, Inc.	RxEVIDICE	87/094588	N/A